Benzinga | Jun 16, 2021 07:04AM EDT

BioCryst Announces Acceptance And Accelerated Review Of The ORLADEYO Marketing Application By The Israeli Ministry Of Health

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older. The Israeli Ministry of Health also has granted an accelerated review. In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd., a corporation organized under the laws of the State of Israel, the exclusive rights to commercialize ORLADEYO in Israel.